Refine by
Industries served
- Medical / Health Care
- Monitoring and Testing
- Chemical & Pharmaceuticals
- Agriculture
- Water and Wastewater
- Manufacturing, Other
- Energy
- Mining
- Banking & Finance / Insurance / Legal
- Electronics and Computers
- Waste and Recycling
- Oil, Gas & Refineries
- Environmental
- Health and Safety
- Air and Climate
- University / Academia / Research
- Government
- Food and Beverage
Tumor Cells Suppliers Near Austria
164 companies found
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
Human (Parental) Brain Cancer Stem Cell (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cell Cultures from single ...
based inIssoire, FRANCE
An allogeneic platform designed to generate first in class immune therapy with the goal of harnessing the patient immune system and preventing resistance to cancer treatment. Our mission at Brenus is to provide a solution to cold solid tumors – ...
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. It is estimated that metastasis is the primary cause of 90% of all cancer-related deaths. Circulating Tumor ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
Trublood is an advanced non-invasive blood test (which provides diagnostically relevant information about cancers via a safe, simple and quick blood draw). Trublood® evaluates blood sample to detect ‘Circulating Tumor ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell ...
based in, CALIFORNIA (USA)
At Delee we’re fundamentally changing not only the way cancer is detected but also how it could be treated. By developing a device capable of capturing Circulating Tumor Cells (CTCs) in a faster and more effective way than the current technologies ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and ...
based inRockville, MARYLAND (USA)
Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...
Solid tumors are complex organ-like structures consisting of cancer cells, vasculature, and tumor matrix. This dense extracellular matrix, also known as stroma, hampers the intratumoral ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM ...
based inSouth San Francisco, CALIFORNIA (USA)
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing ...
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
The NEC Immune Profiler Provides an Holistic Approach to Antigen Presentation Prediction. NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data ...
based inMilan, ITALY
Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer. Tethis’ technology points to standardization of the blood sample preparation to provide ...
based inMannheim, GERMANY
faCellitate is a venture that originated from BASF’s incubator, Chemovator, and it provides interactive consumables for advanced cell technologies and regenerative medicine in the 3D cell culture market. Its unique polymeric platform aims at ...
based inSan Francisco, CALIFORNIA (USA)
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inBeverly, MASSACHUSETTS (USA)
Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical ...
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no ...
based inMontpellier, FRANCE
SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes. SurgiMab was ...